1. Home
  2. ADAG vs NRO Comparison

ADAG vs NRO Comparison

Compare ADAG & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$2.80

Market Cap

222.2M

Sector

Health Care

ML Signal

N/A

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

BUY

Current Price

$2.52

Market Cap

186.3M

Sector

Finance

ML Signal

BUY

Company Overview

Basic Information
Metric
ADAG
NRO
Founded
2011
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
222.2M
186.3M
IPO Year
2020
2003

Fundamental Metrics

Financial Performance
Metric
ADAG
NRO
Price
$2.80
$2.52
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $9.91
N/A
AVG Volume (30 Days)
★ 277.3K
224.2K
Earning Date
08-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$129.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$2.54
52 Week High
$4.85
$3.23

Technical Indicators

Market Signals
Indicator
ADAG
NRO
Relative Strength Index (RSI) 34.86 20.83
Support Level $2.80 N/A
Resistance Level $3.19 $3.09
Average True Range (ATR) 0.29 0.06
MACD -0.01 -0.01
Stochastic Oscillator 16.77 1.82

Price Performance

Historical Comparison
ADAG
NRO

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

Share on Social Networks: